相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
Funda Meric-Bernstam et al.
LANCET ONCOLOGY (2022)
HER2-targeted therapies - a role beyond breast cancer
Do-Youn Oh et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen
Bo Wang et al.
MABS (2020)
DuoHexaBody-CD37(R), a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies
Simone C. Oostindie et al.
BLOOD CANCER JOURNAL (2020)
Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab
Anna Felberg et al.
FRONTIERS IN IMMUNOLOGY (2020)
Bispecific antibodies: a mechanistic review of the pipeline
Aran F. Labrijn et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T
Thomas Nerreter et al.
NATURE COMMUNICATIONS (2019)
Arp2/3 complex-driven spatial patterning of the BCR enhances immune synapse formation, BCR signaling and B cell activation
Madison Bolger-Munro et al.
ELIFE (2019)
The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy
Anne Geller et al.
FRONTIERS IN IMMUNOLOGY (2019)
Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody
Vaheh Oganesyan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
Josep Tabernero et al.
LANCET ONCOLOGY (2018)
cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination
Ali Punjani et al.
NATURE METHODS (2017)
Rigidity of the extracellular part of HER2: Evidence from engineering subdomain interfaces and shared-helix DARPin-DARPin fusions
Christian Jost et al.
PROTEIN SCIENCE (2017)
CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity
Yu Wang et al.
ONCOLOGY LETTERS (2017)
Molecule Counts in Localization Microscopy with Organic Fluorophores
Christos Karathanasis et al.
CHEMPHYSCHEM (2017)
Single molecule localization deep within thick cells; a novel super-resolution microscope
Reza Tafteh et al.
JOURNAL OF BIOPHOTONICS (2016)
ABiparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
John Y. Li et al.
CANCER CELL (2016)
Model-independent counting of molecules in single-molecule localization microscopy
Gerhard Hummer et al.
MOLECULAR BIOLOGY OF THE CELL (2016)
Real-time 3D stabilization of a super-resolution microscope using an electrically tunable lens
Reza Tafteh et al.
OPTICS EXPRESS (2016)
Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS-p110 crosstalk
Rastislav Tamaskovic et al.
NATURE COMMUNICATIONS (2016)
A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface
Rob N. de Jong et al.
PLOS BIOLOGY (2016)
Complement system part I - molecular mechanisms of activation and regulation
Nicolas S. Merle et al.
FRONTIERS IN IMMUNOLOGY (2015)
Combating HER2-overexpressing breast cancer through induction of calreticulin exposure by Tras-Permut CrossMab
Fan Zhang et al.
ONCOIMMUNOLOGY (2015)
HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design
Bart E. C. G. de Goeij et al.
MABS (2014)
Identification of Anti-ErbB2 Dual Variable Domain Immunoglobulin (DVD-Ig™) Proteins with Unique Activities
Jinming Gu et al.
PLOS ONE (2014)
Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
Christoph A. Diebolder et al.
SCIENCE (2014)
Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity
Dominika Rudnicka et al.
BLOOD (2013)
Bispecific Antibody to ErbB2 Overcomes Trastuzumab Resistance through Comprehensive Blockade of ErbB2 Heterodimerization
Bohua Li et al.
CANCER RESEARCH (2013)
Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab
Srinivas Mamidi et al.
MOLECULAR ONCOLOGY (2013)
Improving biophysical properties of a bispecific antibody scaffold to aid developability Quality by molecular design
Thomas Spreter Von Kreudenstein et al.
MABS (2013)
Anti-EGFR biparatopic-SEED antibody has enhanced combination-activity in a single molecule
Christie Kelton et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2012)
Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients
Frank J. Beurskens et al.
JOURNAL OF IMMUNOLOGY (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Evaluation of fluorophores for optimal performance in localization-based super-resolution imaging
Graham T. Dempsey et al.
NATURE METHODS (2011)
Simultaneous multiple-emitter fitting for single molecule super-resolution imaging
Fang Huang et al.
BIOMEDICAL OPTICS EXPRESS (2011)
Anovel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement
Margaret A. Lindorfer et al.
BLOOD (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Statistical Issues in Longitudinal Data Analysis for Treatment Efficacy Studies in the Biomedical Sciences
Chunyan Liu et al.
MOLECULAR THERAPY (2010)
Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions
Gregory L. Moore et al.
MABS (2010)
Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling
Jamie B. Spangler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Complement in antibody therapy: friend or foe?
Martino Introna et al.
BLOOD (2009)
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
Teemu T. Junttila et al.
CANCER CELL (2009)
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
Werner Scheuer et al.
CANCER RESEARCH (2009)
Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX
Andrew W. Pawluczkowycz et al.
JOURNAL OF IMMUNOLOGY (2009)
Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development
Dana Gancz et al.
MOLECULAR IMMUNOLOGY (2009)
Subdiffraction-resolution fluorescence imaging with conventional fluorescent probes
Mike Heilemann et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2008)
Mechanisms of killing by anti-CD20 monoclonal antibodies
Martin J. Glennie et al.
MOLECULAR IMMUNOLOGY (2007)
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB Ligands and remain dependent on the ErbB receptor network
Christoph A. Ritter et al.
CLINICAL CANCER RESEARCH (2007)
Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy
LM Friedman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines
N Prang et al.
BRITISH JOURNAL OF CANCER (2005)
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
MC Franklin et al.
CANCER CELL (2004)
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
MS Cragg et al.
BLOOD (2004)
Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin
CD Austin et al.
MOLECULAR BIOLOGY OF THE CELL (2004)
Molecular approach to breast cancer treatment
Y Yarden et al.
SEMINARS IN ONCOLOGY (2004)
UCSF chimera - A visualization system for exploratory research and analysis
EF Pettersen et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2004)
Complement activation determines the therapeutic activity of rituximab in vivo
N Di Gaetano et al.
JOURNAL OF IMMUNOLOGY (2003)
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
O Manches et al.
BLOOD (2003)
Protection of xenogeneic cells from human complement-mediated lysis by the expression of human DAF, CD59 and MCP
J Huang et al.
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors
I Bergman et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2000)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and Lamm equation modeling
P Schuck
BIOPHYSICAL JOURNAL (2000)
分享论文
